Abstract:THESIS 11122%%%%The objective of this project was to explore clinical and molecular aspects of electroconvulsive therapy (ECT) in the treatment of depression, with a particular focus on the role of microRNAs (small, non-coding molecules that can regulate gene expression). The patients receiving ECT in this study were participants in a randomised controlled trial (the EFFECT-Dep Trial) of high-dose (6x seizure threshold) right unilateral and standard dose (1.5x seizure threshold) bitemporal brief-pulse ECT for depression. The objective of the EFFECT-Dep Trial was to compare the effectiveness and cognitive side-effects of these two forms of ECT. In this thesis, a systematic review and meta-analysis was carried out with a similar objective. PubMed, PsycInfo, Web of Science, Cochrane Library, Embase and the International Clinical Trials Registry Platform databases were searched for with the terms "electroconvulsive" or "electroshock" and "trial". Seven randomised controlled trials (n=792) met inclusion criteria, including the EFFECT-Dep Trial. Bitemporal ECT did not differ from high-dose unilateral ECT on depression rating change scores (Hedges?s g = -0.03; 95% confidence interval (CI) -0.17 to 0.11), remission (RR 1.06; 95% CI 0.93 to 1.20), or relapse at 12-months (RR 1.42; 95% CI 0.90 to 2.23). There was an advantage for unilateral ECT on reorientation time after individual ECT sessions (mean difference in minutes = -8.28; 95% CI -12.86 to -3.70) and retrograde autobiographical memory (Hedges?s g =-0.46, 95% CI=-0.87 to -0.04) after completing an ECT course. There were no differences for general cognition, category fluency and delayed visual and verbal memory. The immediate clinical implication of this is that high-dose right unilateral ECT should be considered as a first-line option when prescribing ECT. Peripheral blood samples from patients participating in the EFFECTDep Trial and healthy controls were collected in PaxGene? bottles. MicroRNAs and mRNAs were extracted using PaxGene? blood miRNA/RNA kits. An initial discovery phase deep sequencing study (n=16) was carried out on the SOLiD? platform. This yielded over 23 million reads mapping on to known microRNAs in the human genome. However, in the group as a whole there were no significant differences in microRNA levels from baseline to ECT following strict correction for multiple testing. However, post-hoc analysis indicated that there were significant changes in microRNA levels in patients with psychotic depression. These changes were confirmed in the same sample using quantitative real-time polymerase chain reaction (qRTPCR). In a separate cohort (37 depressed, 34 controls), candidate microRNAs from deep sequencing were analysed in a validation study. Two microRNAs (miR-126-3p and miR-106a-5p) were significantly elevated in patients with psychotic depression (n=7) at baseline when compared to healthy controls. After ECT treatment, the levels of these microRNAs normalised. Bioinformatic analysis revealed a high number of genes, molecular and biological processes…

Allopregnanolone and progesterone in relation to a single electroconvulsive therapy seizure and subsequent clinical outcome: an observational cohort study

Blood biomarkers of neuronal injury and astrocytic reactivity in electroconvulsive therapy

The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid

Exploring the effects of erythropoietin treatment on cortical thickness and hippocampal volume in patients with mood disorders undergoing electroconvulsive therapy: A randomized, placebo-controlled trial

Seizure Duration and Electroconvulsive Therapy in Major Depressive Disorder

Relationship between Delta Rhythm, Seizure Occurrence and Allopregnanolone Hippocampal Levels in Epileptic Rats Exposed to the Rebound Effect

Place of neurosteroids in the treatment of status epilepticus

Electroconvulsive therapy for depression : optimising treatment and exploring molecular mechanisms

Effect of erythropoietin on cognitive side-effects of electroconvulsive therapy in depression: A randomized, double-blind, placebo-controlled trial

Monitoring Anesthetic Depth Using the Patient State Index in Electroconvulsive Therapy Improves Seizure Quality

No Effect of Serum Electrolyte Levels on Electroconvulsive Therapy Seizure Quality Parameters

The influence of concomitant antidepressant and antipsychotic medication on antidepressant effect and seizure duration of electroconvulsive therapy

Unraveling epigenomic signatures and effectiveness of electroconvulsive therapy in treatment-resistant depression patients: a prospective longitudinal study

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study

Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis

The effect of progesterone and its metabolite 5 alpha-pregnan-3 alpha-ol-20-one on focal epileptic seizures in the cat's visual cortex in vivo

Electroconvulsive Therapy (ECT): A Scotland Wide Naturalistic Study of 4,826 treatment episodes

The effects of treatment, clinical and demographic factors on recovery of orientation after ECT: A care network study

Effects of different indications on electroconvulsive therapy

Etomidate versus Propofol for Electroconvulsive Therapy in Patients with Major Depressive Disorders in Terms of Clinical Responses to Treatment: A Retrospective Analysis

Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment-resistant status epilepticus